LIR Life Sciences Corp.
BBCMF
$0.20
$0.000.00%
OTC PK
| 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 445.37% | 1,577.98% | 357.33% | 182.53% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 473.79% | 1,588.08% | 360.59% | 206.93% | |
| Operating Income | -473.79% | -1,588.08% | -360.59% | -206.93% | |
| Income Before Tax | -561.62% | -1,840.75% | -359.93% | -207.23% | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -561.62% | -1,840.75% | -359.93% | -207.23% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -561.62% | -1,840.75% | -359.93% | -207.23% | |
| EBIT | -473.79% | -1,588.08% | -360.59% | -206.93% | |
| EBITDA | -- | -- | -- | -- | |
| EPS Basic | -330.95% | -138.02% | 98.81% | 99.19% | |
| Normalized Basic EPS | -296.23% | -143.71% | 98.80% | 99.18% | |
| EPS Diluted | -330.95% | -138.02% | 98.81% | 99.19% | |
| Normalized Diluted EPS | -296.23% | -143.71% | 98.80% | 99.18% | |
| Average Basic Shares Outstanding | 53.71% | 714.97% | 38,689.00% | 37,900.00% | |
| Average Diluted Shares Outstanding | 53.71% | 714.97% | 38,689.00% | 37,900.00% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |